Merck gains rights to Abbisko s pimicotinib in deal worth over $70m pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Merck a leading science and technology company today announced a license agreement with Abbisko Therapeutics Co. Ltd. Shanghai China for pimicotinib ABSK021 which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor TGCT.
Merck has entered into a $70 million licensing agreement with Abbisko Therapeutics for pimicotinib, which is currently being evaluated in a phase 3 study for the treatment of tenosynovial giant cell tumor (TGCT).
SHANGHAI, Dec. 4, 2023 /PRNewswire/ On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company.
Merck Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.